January 3, 2012Date Released: 3 January 2012
CASE CCC IN THE NEWS
Mammograms Go 3-D
Cleveland Clinic Researcher Discovers Genetic Cause of Thyroid Cancer
Skin Cancer More Likely After First Malignancy
Breast Cancer Awareness All Year: NetWellness
Healing From Cancer Tops Family's Christmas List
MARK YOUR CALENDARSSpecial Cancer Center Seminar Series: RB-pathway in Translation: Significance to Breast Cancer Treatment
Tuesday, January 3
Please join us today, January 3, at 4 pm in Wolstein 2-136 for a special seminar titled RB-pathway in Translation: Significance to Breast Cancer Treatment, presented by Erik Knudsen, PhD. Dr. Knudsen is the Deputy Director for Basic Research at the Kimmel Cancer Center and Professor of Cancer Biology at Thomas Jefferson University. He has made significant contributions to our understanding of tumor suppressor function, with particular emphasis on RB in various cancers. Most recently, he has delineated a role for RB in regulating therapeutic responsiveness of breast cancer. Among his many accomplishments are membership on the Editorial Board for "Cancer Research" and he has recently chaired the Tumor Cell Biology Study Section. He has also published over 100 primary research articles. In his seminar, Dr. Knudsen will share his most recent insights regarding the use of RB status as a predictor for therapeutic response in breast cancer.NCI Second Symposium on Translational Genomics
Registration is now open for the Second Symposium on Translational Genomics, March 15-16 at the NIH in Bethesda, Maryland. Presented by the NCI Center of Excellence in Integrative Cancer Biology and Genomics, this seminar will provide a dedicated forum for the advancement, implementation, and exchange of information on noncoding RNAs, next generation sequencing, and epigenomics and genetic variation for translation into clinical practice, with the ultimate goal to improve the health of patients with cancer.
NEWS FROM THE NIHNIH Establishes National Center for Advancing Translational Sciences
In a move to re-engineer the process of translating scientific discoveries into new drugs, diagnostics, and devices, the National Institutes of Health has established the National Center for Advancing Translational Sciences (NCATS). The action was made possible by Congress' approval of a fiscal year 2012 spending bill and the president's signing of the bill, which includes the establishment of NCATS with a budget of $575 million.
NCATS will serve as the nation's hub for catalyzing innovations in translational science. Working closely with partners in the regulatory, academic, nonprofit, and private sectors, NCATS will strive to identify and overcome hurdles that slow the development of effective treatments and cures.
Please join us in welcoming the newest members of the Case CCC:
Ramon Tiu, MD
Carl Tyler, MD
Vikas Gulani, MD, PhD
Efstathios Karathanasis, PhD
Justin Lathia, PhD
Sonja Harris-Haywood, MD
In November 2011, 539 individuals were elected as Fellows of the American Association for the Advancement of Science (AAAS). The Case CCC is honored to have three researchers from our institutions recognized for their contributions to science and technology: Xiaoxia Li and Michael Ledermanfor Medical Sciences and Bruce Lamb for Neuroscience.
FUNDING OPPORTUNITIESAmerican Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Annual Meeting Merit Awards
The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) offers Merit Awards to trainees who submit high-quality abstracts selected for presentation at an ASCO Meeting. To be considered for a Merit Award, the first author of an abstract must be a physician (MD, PharmD, PhD, DO, or other doctoral degree) enrolled in an oncology training program at the time of abstract submission, work in an oncology laboratory or clinical research setting, and agree to present the abstract at the ASCO Annual Meeting. Candidates must apply for this award at the time of abstract submission.
The Damon Runyon Cancer Research Foundation has joined together with the Sohn Conference Foundation, dedicated to curing pediatric cancers, to establish the Damon Runyon-Sohn Pediatric Cancer Fellowship Award. This award provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers. Only one fellowship application will be accepted from a Sponsor or Fellow per review session; there is no limit, however, to the number of applications from an institution.
**All events are open to anyone interested in attending
Happy New Year!
Special Cancer Center Seminar Series
Hematology and Oncology Division Research Conference
Molecular Biology & Microbiology Seminar
Cancer Center Seminar Series canceled
Hem/Onc Fellows Conference
Taussig Cancer Institute Grand Rounds
CAP Promotion Seminar
Cancer Center Research in Progress Seminar
Case CCC Calendar
UPCOMING CANCER CENTER SYMPOSIUMS & EVENTS
ADDITIONAL UPCOMING SEMINARS & EVENTS
Berman Lecture/Department of Medicine Grand Rounds
Department of Biomedical Engineering Special Seminar
PREVIOUSLY ANNOUNCED OPPORTUNITIES
National Center of Regenerative Medicine (NCRM) Stem Cell-related Pilot Projects
2012 Lasker Awards
NIH BULLETIN – Notices and Funding Opportunities
Small Grants for Behavioral Research in Cancer Control (R03)(PAR-12-035)
The NCI Transition Career Development Award to Promote Diversity (K22)(PAR-12-062)
NCI Established Investigator Award in Cancer Prevention and Control (K05)(PAR-12-065)
Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07)(PAR-12-067)
Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D43)(PAR-12-068)
Early-Stage Innovative Technology Development for Cancer Research (R21) (RFA-CA-12-002)
Validation and Advanced Development of Emerging Technologies for Cancer Research (R33)(RFA-CA-12-003)
Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science (R21)(RFA-CA-12-004)
Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33)(RFA-CA-12-005)
Notice of Two Pilot Processes for Submitting Administrative Supplement Requests Electronically to NIH (NOT-OD-12-024)
Innovative Molecular Analysis Technologies (IMAT) for Cancer Research Selection of Appropriate Funding Opportunity (NOT-CA-12-006)
Extension of Expiration Date for NCI Funding Opportunity Announcement PAR-09-089: The NCI Transition Career Development Award (K22) (NOT-CA-12-010)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!
Send items to email@example.com.